CN100366624C - 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物 - Google Patents

2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物 Download PDF

Info

Publication number
CN100366624C
CN100366624C CNB2003801017508A CN200380101750A CN100366624C CN 100366624 C CN100366624 C CN 100366624C CN B2003801017508 A CNB2003801017508 A CN B2003801017508A CN 200380101750 A CN200380101750 A CN 200380101750A CN 100366624 C CN100366624 C CN 100366624C
Authority
CN
China
Prior art keywords
group
halogen
substituted
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2003801017508A
Other languages
English (en)
Chinese (zh)
Other versions
CN1705670A (zh
Inventor
壶内英继
佐佐木博文
黑田英明
糸谷元宏
长谷川武司
原口佳和
黑田武志
松崎敬之
田井国宪
小松真
松本真
桥诘博之
富重辰夫
清家祐治
川崎昌则
住田卓美
宫村伸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN1705670A publication Critical patent/CN1705670A/zh
Application granted granted Critical
Publication of CN100366624C publication Critical patent/CN100366624C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB2003801017508A 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物 Expired - Lifetime CN100366624C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP298259/2002 2002-10-11
JP2002298259 2002-10-11

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CNA2007100040367A Division CN101172981A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CN201110416170.4A Division CN102532162B (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物
CNA2007100040371A Division CN101255170A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物

Publications (2)

Publication Number Publication Date
CN1705670A CN1705670A (zh) 2005-12-07
CN100366624C true CN100366624C (zh) 2008-02-06

Family

ID=32089299

Family Applications (4)

Application Number Title Priority Date Filing Date
CNB2003801017508A Expired - Lifetime CN100366624C (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CNA2007100040371A Pending CN101255170A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CNA2007100040367A Pending CN101172981A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CN201110416170.4A Expired - Lifetime CN102532162B (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CNA2007100040371A Pending CN101255170A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CNA2007100040367A Pending CN101172981A (zh) 2002-10-11 2003-10-10 2,3－二氢－6－硝基咪唑并[2,1－b]唑化合物
CN201110416170.4A Expired - Lifetime CN102532162B (zh) 2002-10-11 2003-10-10 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物

Country Status (26)

Country Link
US (1) US7262212B2 (enExample)
EP (2) EP1555267B1 (enExample)
JP (1) JP4186065B2 (enExample)
KR (1) KR100723847B1 (enExample)
CN (4) CN100366624C (enExample)
AR (4) AR041198A1 (enExample)
AU (1) AU2003272979B2 (enExample)
BE (1) BE2014C053I2 (enExample)
BR (1) BRPI0314344B8 (enExample)
CA (1) CA2497569C (enExample)
CY (2) CY1113578T1 (enExample)
DK (1) DK1555267T3 (enExample)
ES (1) ES2400179T3 (enExample)
FR (1) FR14C0066I2 (enExample)
HU (1) HUS1400046I1 (enExample)
LU (1) LU92517I2 (enExample)
MX (1) MXPA05003674A (enExample)
MY (1) MY139244A (enExample)
PL (3) PL404913A1 (enExample)
PT (1) PT1555267E (enExample)
RU (1) RU2326121C3 (enExample)
SI (1) SI1555267T1 (enExample)
TW (1) TWI347946B (enExample)
UA (1) UA83200C2 (enExample)
WO (1) WO2004033463A1 (enExample)
ZA (1) ZA200501033B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7368579B2 (en) 2002-10-15 2008-05-06 Otsuka Pharmaceutical Co., Ltd. 1-substituted-4-nitroimidazole compound and process for producing the same
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
ATE410430T1 (de) 2003-10-31 2008-10-15 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
PT1731518E (pt) 2004-03-31 2014-09-18 Nippon Soda Co Composto amina cíclico e agente de controlo de pragas
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
ATE450525T1 (de) * 2005-06-20 2009-12-15 Schering Corp Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten
EP1906926B1 (en) * 2005-07-28 2010-12-01 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole derivatives
TWI368509B (en) * 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
BRPI0616667B1 (pt) 2005-10-06 2017-07-18 Nippon Soda Co. , Ltd. Compounds of cyclical amine or salts thereof or non-oxides thereof, and agents for control of fever
TW200800268A (en) 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
CA2640304A1 (en) * 2006-02-13 2007-08-23 Laboratoires Serono S.A. Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
US8575156B2 (en) * 2007-07-26 2013-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CL2008002384A1 (es) * 2007-08-15 2009-07-17 Glaxo Group Ltd Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
WO2009050204A1 (en) * 2007-10-16 2009-04-23 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
JP5613656B2 (ja) * 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ588954A (en) 2008-05-01 2012-08-31 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201004945A (en) 2008-05-01 2010-02-01 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN104327062A (zh) 2008-07-25 2015-02-04 贝林格尔·英格海姆国际有限公司 11β-羟基类固醇脱氢酶1的环状抑制剂
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CA2733554A1 (en) * 2008-08-18 2010-02-25 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EP2323990B1 (en) * 2008-08-21 2014-06-18 Dynamit Nobel GmbH Explosivstoff- und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ598121A (en) * 2009-07-31 2013-04-26 Global Alliance For Tb Drug Dev Nitroimidazooxazines and their uses in anti-tubercular therapy
ES2530266T3 (es) * 2009-07-31 2015-02-27 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina y sus usos
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
WO2011052522A1 (ja) 2009-10-26 2011-05-05 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) * 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
CN103596960B (zh) 2011-04-15 2016-11-16 大塚制药株式会社 6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
IN2013DE02954A (enExample) 2013-10-04 2015-04-10 Council Scient Ind Res
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
AR101704A1 (es) 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
CN107108650B (zh) * 2014-10-21 2019-10-18 印度科学工业研究所 抗分枝杆菌剂取代的1,2,3-三唑-1-基-甲基-2,3-二氢-2-甲基-6-硝基咪唑并[2,1-b]噁唑及其制备方法
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
MX2017009810A (es) * 2015-01-29 2018-11-09 Medshine Discovery Inc Derivado de nitroimidazol contra tuberculosis pulmonar.
EP3275862B1 (en) 2015-03-27 2020-08-12 Otsuka Pharmaceutical Co., Ltd. Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
EP3421454B9 (en) 2016-02-26 2023-08-09 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
MX2019000858A (es) * 2016-07-22 2019-11-11 Medshine Discovery Inc Cristal y sal de nitroimidazol y metodo de fabricacion de los mismos.
PH12020500339A1 (en) * 2017-08-16 2024-02-05 BioVersys AG Novel compounds
KR102887592B1 (ko) 2018-06-11 2025-11-18 오츠카 세이야쿠 가부시키가이샤 델라마니드 함유 조성물
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN119522100A (zh) 2022-07-29 2025-02-25 大塚制药株式会社 含有德拉马尼的固体分散体
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
In vitro and in vivo activities of the nitroimidazole CGI 17341AGAINST MYCOBACTERIUM TUBERCULOSIS. Ashtekar等人.ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,Vol.37 No.2. 1993 *
NITROIMIDAZOLES. NAGARAJAN等人.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,Vol.24 No.6. 1989 *
Potential radiosensitizing agents. Sehgal等人.JOURNAL OF MEDICINAL CHEMISTRY,Vol.24 No.5. 1981 *

Also Published As

Publication number Publication date
BR0314344A (pt) 2005-07-12
EP1555267A4 (en) 2010-08-18
AU2003272979A1 (en) 2004-05-04
CY2014041I2 (el) 2016-07-27
JP2004149527A (ja) 2004-05-27
EP2570418A3 (en) 2013-07-03
RU2005114017A (ru) 2006-01-20
US7262212B2 (en) 2007-08-28
FR14C0066I1 (enExample) 2014-10-17
US20060094767A1 (en) 2006-05-04
HK1085463A1 (zh) 2006-08-25
KR20050061473A (ko) 2005-06-22
DK1555267T3 (da) 2013-02-11
CN101255170A (zh) 2008-09-03
BRPI0314344B8 (pt) 2021-05-25
EP1555267A1 (en) 2005-07-20
FR14C0066I2 (fr) 2015-05-22
CN102532162B (zh) 2015-05-27
HK1171018A1 (en) 2013-03-15
AR089950A2 (es) 2014-10-01
PT1555267E (pt) 2013-01-29
TW200420568A (en) 2004-10-16
MXPA05003674A (es) 2005-06-08
CN101172981A (zh) 2008-05-07
LU92517I2 (fr) 2014-10-13
SI1555267T1 (sl) 2013-05-31
UA83200C2 (en) 2008-06-25
AR041198A1 (es) 2005-05-04
MY139244A (en) 2009-09-30
AU2003272979B2 (en) 2009-07-23
PL409525A1 (pl) 2014-11-10
BE2014C053I2 (enExample) 2022-08-30
CA2497569C (en) 2011-05-24
KR100723847B1 (ko) 2007-05-31
CY1113578T1 (el) 2016-06-22
EP2570418A2 (en) 2013-03-20
CN102532162A (zh) 2012-07-04
RU2326121C2 (ru) 2008-06-10
JP4186065B2 (ja) 2008-11-26
BRPI0314344B1 (pt) 2019-11-26
PL217919B1 (pl) 2014-09-30
CA2497569A1 (en) 2004-04-22
RU2326121C3 (ru) 2021-09-17
TWI347946B (en) 2011-09-01
CY2014041I1 (el) 2016-07-27
CN1705670A (zh) 2005-12-07
PL376157A1 (en) 2005-12-27
PL404913A1 (pl) 2013-09-30
AR086485A2 (es) 2013-12-18
WO2004033463A1 (ja) 2004-04-22
HUS1400046I1 (hu) 2017-04-28
EP1555267B1 (en) 2013-01-16
ES2400179T3 (es) 2013-04-08
ZA200501033B (en) 2006-06-28
AR091771A2 (es) 2015-02-25

Similar Documents

Publication Publication Date Title
CN100366624C (zh) 2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CN104822687B (zh) 抗纤维化吡啶酮类
TWI457333B (zh) 嗒酮化合物
JP4787529B2 (ja) 医薬組成物
CN105745206B (zh) 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
CN106715440B (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
CN111377917A (zh) 杂环类化合物、中间体、其制备方法及应用
WO2002032872A1 (fr) Composes a noyau aromatique azote
CN108191861B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN107001271B (zh) 羟基脒类衍生物、其制备方法及其在医药上的应用
WO2022166974A1 (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
WO2020103817A1 (zh) TGF-βR1抑制剂及其应用
JP5345174B2 (ja) 医薬組成物
CN108017633A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
HK1171018B (en) 2,3-dihydro-6-nitroimidazo (2, 1-b) oxazoles
HK1085463B (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK1259107A1 (zh) 氨基唑衍生物
HK1118543A (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK40050827B (zh) 蛋白酶体活性增强化合物
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK1181049A (en) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085463

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1085463

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20080206

CX01 Expiry of patent term